The Diabetes Control and Complications Trial
Research Group (1993) TO THE EDITOR Dominant dystrophic epidermolysis bullosa (DDEB) is a rare genetic blistering skin disorder with no known cure. The disorder is caused by mutations in the COL7A1 gene leading to weakened a1(VII) (collagen VII) homotrimers, whose function is to knit epidermal and dermal skin layers together (Parente et al., 1991; McGrath et al., 1993) . Over 60 COL7A1 mutations have been implicated in DDEB, making this disorder, similar to many other dominant disorders, extremely heterogenous (Nakamura et al., 2004) . A gene therapy strategy for DDEB involving suppression of mutant COL7A1 transcripts using allele-specific RNA interference (RNAi) molecules targeting a mutation site has been adopted in vitro (Pendaries et al., 2012) . This informative study demonstrated potent and specific RNAi-mediated allelespecific suppression of a COL7A1 splice-site mutation in cells; similar levels of RNAi specificity have been obtained by others (Hickerson et al., 2008; Lindahl et al., 2008; Atkinson et al., 2011) . In contrast, for many COL7A1 mutations and indeed other target genes, allele-specific RNAi suppression has not been achieved (de Yñigo-Mojado et al., 2011; Pendaries et al., 2012 and Morgan et al., unpublished data) .
Given the vast array of COL7A1 mutations implicated in DDEB, the development of RNAi-mediated mutationspecific therapies targeting each mutant is not technically/economically feasible. In this study, we have addressed the substantial problem of DDEB-associated mutational heterogeneity and have tested four mutation-independent small interfering RNAs (siRNAs; si1-si4) targeting different regions of the COL7A1 gene ( Figure 1d) . A single potent mutation-independent suppressor in conjunction with a replacement gene designed to be refractory to suppression represents a therapy for DDEB, which corrects the primary genetic defect, but in a mutation-independent manner.
The two elements of this dual-component therapy for DDEB were evaluated as follows: si1-si4 targeting positions 733-753, 6,356-6,376, 5,384-5,404 , and 2,902-2,922 of the COL7A1 sequence (NM_000094), respectively, and a nontargeting control siRNA (NT) were tested (Supplementary Materials and Methods online). In 24-well plates, 5 nM si1-si4 and control NT were transfected into 1 Â 10 5 keratinocytes, HaCaTs (Boukamp et al., 1988) . RNA was isolated 24 hours after transfection (Allen et al., 2008) . COL7A1 RNA levels were suppressed significantly by si1-si4 by 65 ± 9%, 50 ± 13.5%, 71 ± 8.7%, and 68 ± 3.7%, respectively (n ¼ 4; Po0.001; Figure 1a ). Short hairpin RNA equivalents of si1, si3, and si4 (sh1, sh3, and sh4) were generated (Brummelkamp et al., 2002) , and after transfection into immortalized HaCaT cells significant suppression of COL7A1 transcript levels of 73 ± 3.4%, 57 ± 2.4%, and 49 ± 15%, respectively, was demonstrated (n ¼ 3; Po0.001; Figure 1a) .
Notably, suppression of COL7A1 transcript was also confirmed in primary cells, normal human dermal fibroblast primary cells, and significant suppression levels of 75 ± 13.7%, 60 ± 17.7%, 79 ± 8.5%, and 77 ± 12% were demonstrated with si1-si4, respectively (n ¼ 3; Po0.001; Figure 1c) . Similarly, in HaCaT cells, suppression at the protein level by the most efficient siRNA, si3, was clearly visible by western blotting 48 hours after RNAi transfection ( Figure 1b) .
The most potent RNAi molecule, si3, was investigated further for this mutation-independent suppression and replacement therapeutic strategy for DDEB and a replacement COL7A1 gene (R) was generated with altered degenerate nucleotides at the si3 target site (Figure 2a ). Alterations in codon usage was minimized when designing R by using conservative codon changes, and thus expression levels would be optimal. As the transcript expressed from R contains six-nucleotide mismatches (Figure 2a in red) at the si3 target site, it was expected that, although R encodes wild-type Collagen VII protein, RNAi suppression by si3 should be minimal or eliminated.
Indeed, when 0.6 mg R and 1.25 nM of si3 or NT were co-transfected in a six-well plate into HEK293 cells, R transcript was not suppressed significantly by si3 (Supplementary Materials and Methods online). In contrast, wildtype COL7A1 RNA was suppressed by 77 ± 11% by si3 compared with the non-targeting RNAi (NT) (n ¼ 3; Po0.001), and no expression of wildtype COL7A1 RNA was observed in untransfected cells (Figure 2b and c) . Similarly, at the protein level, replacement Collagen VII protein was not suppressed by si3, as evaluated by western blotting, whereas the wild-type protein was noticeably reduced ( Figure  2b and c). Hence, we have clearly demonstrated that R RNA is resistant to suppression by si3, whereas wild-type COL7A1 is potently suppressed by B80%.
DDEB is a debilitating, untreatable condition for which development of gene therapies has been hampered by TO THE EDITOR Dermatomyositis (DM) is a rare systemic autoimmune disease characterized by inflammation of the skin and muscle. Skin rash in DM may precede the onset of muscle disease by months to years, and in some cases overt muscle disease may remain mild or never occur. DM skin disease manifests in varied ways including facial edema, pink to violaceous patches on the eyelids (heliotrope sign), violaceous scaly plaques with atrophy on the shoulders and hips, violaceous atrophic scaling papules on the interphalangeal joints (Gottron's papules), and prominent nailfold telangiectasias. However, these findings are variably present, and DM skin disease can share clinical features with cutaneous lupus, overlap connective tissue disease syndromes, UV light-induced reactions, and psoriasis (Sontheimer, 2002) , often creating diagnostic difficulty at early presentation. Psoriasis is an inflammatory skin disease most commonly characterized by well-demarcated plaques with micaceous scales. Histopathologically, psoriasis displays epidermal acanthosis, confluent parakeratosis, subcorneal neutrophils, and thinning of the suprapapillary plate. In contrast, DM is characterized by an interface dermatitis with a superficial perivascular infiltrate, and dermal mucin deposition. However, DM patients often present with erythematous scaly plaques in the scalp or on extremities, which can be clinically confused with psoriasis. In addition, many skin biopsies of DM can actually show minimal to no interface dermatitis, and have evidence of neutrophilic inflammation (Ito et al., 1995; Caproni et al., 2004) , perivascular dermatitis, and even epidermal hyperplasia not dissimilar to that seen in psoriasis.
Molecular profiling has widely been used to aid the diagnosis of cancer patients since the publication of landmark work by Golub et al. (1999) . It has also been applied in autoimmune diseases such as systemic lupus erythematosus for similar purposes (Chaussabel et al., 2008) . In this report, we compare the molecular features of DM and psoriasis and apply molecular profiling to aid in the diagnosis of an ambiguous case of DM.
Our index case, a 32-year-old woman, presented in June 2005 with the 3-month onset of well-demarcated violaceous erythematous, scaling plaques on her elbows, extensor forearms, dorsal hands, lateral thighs, knees, and lower legs, concerning for either psoriasis or Gottron's sign of DM (Figure 1a-c) . Diffuse erythema was also present on her scalp and periungual areas, but she did not display psoriatic nail changes, geographic tongue, or heliotrope sign. Antinuclear antibodies were positive (titer 1:2,560) with a homogenous pattern. Other antibodies including anti-Jo1, SSA, SSB, anti-dsDNA, and anti-centromere were negative. Given her clinical ambiguity, a biopsy of one of these psoriasis-like lesions on the knee was performed. The biopsy demonstrated regular epidermal acanthosis, parakeratosis, mild, superficial perivascular infiltrate, and dilated papillary dermal vessels consistent with psoriasis ( Figure 1d ). No interface dermatitis was detected. However, a colloidal iron stain revealed abundant mucin throughout the dermis (Figure 1e ), which is unusual in psoriasis and more consistent with DM. Given the inconclusive results from traditional histopathology, genome-wide expression analysis was applied to determine 
